MPB-1734 is under clinical development by MegaPro Biomedical and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MPB-1734’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MPB-1734 overview

MPB-1734 is under development for the treatment of advanced solid tumors. It is administered through intravenous route. The drug candidate is being developed based on nano-encapsulation technology platform.

MegaPro Biomedical overview

MegaPro Biomedical is a Taiwan-based company mainly engaged in the development of new drugs with nanomedicine as the core. The Company mainly has two nanotechnology platforms including nanoparticle and nanocell. It is headquartered in Hsinchu, Taiw

For a complete picture of MPB-1734’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.